Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Employer
-
Field
-
6,500 people supporting the three main missions of the institutions: education, research and innovation. The EPFL campus offers an exceptional working environment at the heart of a community of more
-
interpret experimental data to develop mechanistic understanding Contribute to the development of new concepts for electrolyte-controlled electrocatalysis Present your work at international conferences and
-
of thought, background and experience creates better research. ETH Zurich is one of the world’s leading universities specialising in science and technology. We are renowned for our excellent education, cutting
-
of the world’s leading universities specialising in science and technology. We are renowned for our excellent education, cutting-edge fundamental research and direct transfer of new knowledge into society. Over
-
. Temurkhan Ayupov. IOB combines basic and clinical research to advance the understanding of vision and its diseases and to develop new therapies for vision loss. We offer an environment where your expertise
-
, experience and areas in which they would like to develop further expertise. Job description As a doctoral researcher, you will develop a dissertation in applied macroeconomics, public finance and/or political
-
collaboratively in a research-focused environment. Project background We train open foundation models with hundreds of billions of parameters on thousands of GPUs on one of the largest AI-ready supercomputers in
-
track record of open-source contributions. Project background We train open foundation models with hundreds of billions of parameters on thousands of GPUs on one of the largest AI-ready supercomputers in
-
. We train open foundation models with hundreds of billions of parameters on thousands of GPUs on one of the largest AI-ready supercomputers in Europe. The team counts more than a dozen full-time
-
. This project aims to identify novel tumor-reactive T-cell receptors (TCRs) that can be translated into next-generation adoptive T-cell therapies. The successful candidate will develop patient-derived tumor